


6/Friess
Artwall

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/674,624
 Filed: November 3, 2000
 1st Inventor: A. Fujishima
 For: Benzimidazole Compound Crystal
 Atty. Dkt. No. 2635 USOP



Art Unit: 1625
 Examiner: J. Fan
 Allowed:
 Batch:
 Paper No.: 6

MAR 21 2002

TECH CENTER 1600/2900

RECEIVED

Supplemental Information Disclosure Statement

Commissioner for Patents
 Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449 under §1.97(c).

No Final Office Action or Notice of Allowance has been mailed in this case.

Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account number 500799 for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a Supplemental Information Disclosure Statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

03/20/2002 AOSMANI 00000016 500799 09674624

01 FC:126 180.00 CH

Dated: March 15, 2002

(847) 383-3391
 (847) 383-3372

Elaine M. Ramesh

Elaine M. Ramesh, Ph.D., Reg. No. 43,032
 Mark Chao, Ph.D., Reg. No. 37,293
 Attorney for Applicants
 Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
 Intellectual Property Department
 Suite 500, 475 Half Day Road
 Lincolnshire, IL 60069 USA